Patents by Inventor Katherine Meyer Siegler

Katherine Meyer Siegler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7897349
    Abstract: The present invention relates to the association between detecting and quantifying the presence of macrophage migration inhibitory factor (MIF) in urine, bladder and prostate tissues for the purpose of diagnosis and prognosis of urological inflammatory. In addition, methods to inactivate MIF activity by use of antibodies or specific MIF inhibitors can be used to treat these diseases. For instance, such diseases as chronic pelvic pain syndrome, non-bacterial prostatitis, and interstitial cystitis may be mediated by MIF release. Periodic assays for MIF could be conducted for a patient to determine if the patient's MIF urine levels are high or increasing. In addition, intravesical MIF antibodies or other MIF-specific inhibitors would reduce or ameliorate these pelvic diseases.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: March 1, 2011
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventors: Katherine Meyer Siegler, Pedro L. Vera
  • Publication number: 20090275521
    Abstract: The present invention relates to modulating, neutralizing, or inactivating the activity of migration inhibitory factor (MIF). In particularm, the present invention provides methods for modulating, neutralizing, or inactivating MIF activity by complexing MIF with other molecules, preferably a protein, that is capable of associating with MIF. These molecules can be used for treating diseases by the regulation of MIF activity.
    Type: Application
    Filed: December 29, 2005
    Publication date: November 5, 2009
    Inventors: Katherine Meyer-Siegler, Pedro Vera
  • Publication number: 20090035301
    Abstract: The present invention relates to the diagnosis and treatment of bladder cancer. More specifically, this invention uses the levels of macrophage migration inhibitory factor (MIF) produced by the bladder epithelia (urothelia) as a marker for bladder cancer. Moreover, the present invention also provides a method for attenuating bladder carcinoma by inhibiting of macrophage MIF.
    Type: Application
    Filed: July 31, 2008
    Publication date: February 5, 2009
    Applicant: The United States of America Department of Veterans Affairs
    Inventors: Katherine Meyer Siegler, Pedro L. Vera
  • Patent number: 7361474
    Abstract: The present invention provides methods for detecting, diagnosing or prognosticating prostate cancer by measuring the levels of macrophage migration inhibitory factor (MIF) in the serum of an individual. The assay for MIF can be an immunoassay, such as ELISA, or a nucleic assay, such as Nouthern blot. Genetic changes within MIF gene can predict patients that express high levels of MIF.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: April 22, 2008
    Assignee: United States of America as represented by The Department of Veterans Affairs
    Inventor: Katherine Meyer Siegler
  • Publication number: 20040171021
    Abstract: The present invention provides methods for detecting, diagnosing or prognosticating prostate cancer by measuring the levels of macrophage migration inhibitory factor (MIF) in the serum of an individual. The assay for MIF can be an immunoassay, such as ELISA, or a nucleic assay, such as Nouthern blot. Genetic changes within MIF gene can predict patients that express high levels of MIF.
    Type: Application
    Filed: December 17, 2003
    Publication date: September 2, 2004
    Inventor: Katherine Meyer Siegler